NHS set for digital health tech review
October 30, 2015Medical Communications Jeremy Hunt, NHS, Robert Wachter, digital health, health secretary
Health secretary Jeremy Hunt says turning the NHS into a “patient-powered, technologically advanced health service” is “one of the most …
Digital software shows benefit in ADHD trial
October 30, 2015Medical Communications ADHD, Akili, PureTech Health, attention deficit hyperactivity disorder, digital tech
A pilot study of a digital health technology designed to improve symptoms of attention deficit hyperactivity disorder (ADHD) in children …
Sanofi recalls allergy injection pens
October 29, 2015Manufacturing and Production Allerject, Sanofi, anaphylaxis
Sanofi has halted manufacturing and is recalling its Allerject auto-injectors following a blunder involving incorrect dosages. The voluntary recall involves …
Alvogen appoints Faysal Kalmoua as EVP of portfolio
October 29, 2015Medical Communications Alvogen, Faysal Kalmoua
Alvogen has announced the appointment of Faysal Kalmoua as its new executive vice president of portfolio.Kalmoua joins Alvogen with an …
Allergan acquires rights to pioneering IBS treatment from Almirall
October 29, 2015Medical Communications, Sales and Marketing Allergan, Constella, IBS, linaclotide
Allergan and its commercialisation partner Ironwood Pharmaceuticals have announced that Allergan has acquired the rights to Constella.The companies have acquired …
ANALYSIS: The challenges of forecasting biosimilar sales across Europe
October 29, 2015Manufacturing and Production, Research and Development, Sales and Marketing biologics, biosimilars, generics, patent cliff, patents, sales, sales forecasts
The introduction of biologic medicines revolutionised treatment in several key therapeutic areas, including oncology, diabetes and various inflammatory diseases.The landscape …
FDA approves Bristol-Myers Squibb’s skin cancer drug
October 29, 2015Sales and Marketing BMS, Bristol-Myers Squibb, Yervoy, ipilumumab, melanoma
The FDA has recommended Bristol-Myers Squibb’s cancer drug Yervoy (ipilimumab) for the adjuvant treatment of patients with melanoma. The drug, …
Novo Nordisk posts strong nine-month results
October 29, 2015Sales and Marketing Novo Nordisk, insulin
Novo Nordisk has exceeded market expectations in its nine-month financial results, reporting a 51% increase in operating profit and 33% …
Bayer posts strong earnings growth
October 29, 2015Manufacturing and Production, Research and Development, Sales and Marketing
Sales across the Bayer group rose by 1.9% in the third quarter of 2015 to €11 billion, according the company’s …
Novartis launches new hypertension program in Ghana
October 29, 2015Research and Development
The Novartis Foundation and its partners have begun screening patients in a Community-based Hypertension Improvement Project (ComHIP) in Ghana in …
Pfizer in ‘friendly’ merger talks with Allergan
October 29, 2015Sales and Marketing Actavis, Allergan, Pfizer, Teva
Pfizer is in talks with Allergan over what could be the largest takeover deal in an already record-breaking year, it …
Baxter names José Almeida chairman and chief executive
October 29, 2015Manufacturing and Production, Research and Development, Sales and Marketing Joe Almeida, José Almeida, baxter
Baxter has named José (Joe) Almeida as the company’s new chairman and chief executive from January 1, 2016. Almeida will …
Dr Jane Osbourn to join BIA board as chair
October 28, 2015Dr Jane Osbourn, the vice president of research and development at MedImmune, will be the new chair of the BIA …
FDA approves first-in-class Amgen melanoma drug
October 28, 2015Research and Development, Sales and Marketing Amgen, Imlygic, melonoma
The US Food and Drug Administration (FDA) has approved Amgen’s Imlygic for the treatment of melanoma lesions in the skin …
Otsuka kidney drug earns first NICE nod
October 28, 2015Research and Development, Sales and Marketing NHS, NICE, jinarc, kidney disease, tolvaptan
NICE has released final guidance recommending Otsuka’s Jinarc, the first-ever treatment shown to slow progression of life-threatening Autosomal Dominant Polycystic …
Sales up at MSD while Keytruda hits survival target in late-stage trial
October 28, 2015Research and Development, Sales and Marketing MSD, Merck, financial results, keytruda, pembrolizumab
Worldwide sales at MSD were $10.1 billion in the third quarter of 2015, a 4% increase after accounting for the …
Otsuka, GW announce Sativex fails in Phase III cancer pain trials
October 28, 2015Research and Development, Sales and Marketing Cancer, GX Pharmaceuticals, Otsuka, Sativex, cancer pain, palliative care, phase III, phase III failure
Otsuka and GW Pharmaceuticals cannabis-based drug Sativex failed to show superiority over placebo in two Phase III trials.The studies were …
OPINION: ‘More work remains if biosimilars are to fulfil their potential’
October 27, 2015Manufacturing and Production, Research and Development, Sales and Marketing British Generic Manufacturers Association, NHS, bgma, biosimilars, generics, patent cliff, patents
Despite having a mature generics market which fulfils more than three-quarters of all prescriptions in the UK, and as a …
Pharma reaction to the Government’s AAR review
October 27, 2015Manufacturing and Production, Research and Development Accelerated Access Review
The long-awaited interim report on the Government’s Accelerated Access Review has been published.The Government department overseeing the report, the Office …
New Phase III data puts Shire’s lifitegrast back on track for 2016 launch
October 27, 2015Research and Development Shire, dry eye disease, lifitegrast
Shire shares rose 6% today as the company reported new positive Phase III trial data for lifitegrast in the treatment …
Latest content
AstraZeneca’s Trixeo approved in EU for asthma
ESTEVE CDMO adds $17.5m to Illinois expansion
